Navigation Links
Halocarbon Announces Licensing Agreement with IBM
Date:9/19/2009

Halocarbon has long produced hexafluoroisopropanol (HFIP) and has now entered into a licensing agreement with IBM to access IBM's industry-leading portfolio of patents related to hexafluoroisopropanol-based photoresists for semiconductor manufacturing.

River Edge, NJ (PRWEB) -- Halocarbon Products Corporation (www.halocarbon.com), a leading worldwide producer of specialty fluorochemicals, has entered into a licensing agreement with IBM to access IBM's industry-leading portfolio of patents related to hexafluoroisopropanol-based photoresists for semiconductor manufacturing.

"Halocarbon has long produced hexafluoroisopropanol (HFIP) as a key component in the manufacture of the anesthetic sevoflurane," said Halocarbon CEO Peter Murin. "With this agreement, we can partner our fluorochemicals development and manufacturing expertise with IBM's leadership in developing advanced electronic materials such as photoresists."

"This agreement will allow us to leverage our HFIP business and provide reliable, regular, cost-effective, US-based production of advanced photoresist compounds," added Murin.

About Halocarbon
With headquarters in River Edge, New Jersey, and a state-of-the-art manufacturing plant in North Augusta, South Carolina, USA, Halocarbon is one of the world's leading producers of specialty fluorochemicals. Halocarbon products include inert lubricants, aliphatic fluorochemicals for pharmaceutical and agricultural chemical manufacturing, inhalation anesthetics and other specialty products. For more information, please contact the company at +1-201-262-8899 or at www.halocarbon.com.

# # #

Read the full story at http://www.prweb.com/releases/2009/09/prweb2904564.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012
2. AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US
3. LCA-Vision Announces CEO Resignation
4. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
5. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
6. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
7. Aethlon Medical, Inc. Announces Annual Meeting Results
8. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
9. Martek Announces Addition to Its Board of Directors
10. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
11. BVGH Announces New Board Chair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):